Eli Lilly

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

1 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities Just now (09:54 AM IST)

Lilly’s Latest Weight-Loss Drug Drives Up to 60-Pound Loss in Diabetes Trial

Eli Lilly said its experimental triple-agonist drug retatrutide produced striking weight loss and meaningful blood-sugar improvements in people with type 2 diabetes, adding to the company’s lead in the fast-expanding obesity and metabolic disease market. The results intensify investor focus on a drug class that could reshape treatment standards and expand the commercial race against rival therapies.

By RDU Global Wire5 min read

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Eli Lilly:

Washington, D.C.(1)